19 :1-5 Key words: type 2 diabetes, cardiovascular outcome studies, pioglitazone, SGLT2 inhibitors, GLP-1 receptor agonist In previous editorials 1-4 we proposed that metformin, pioglitazone, sodium glucose transporter 2 (SGLT2) inhibitors (in particular empagliflozin and canagliflozin) and long-acting glucagon-like peptide-1 (GLP-1) receptor agonists (in particular liraglutide) in combination could complement each other to prevent cardiovascular events and save lives in patients with type 2 diabetes at high cardiovascular risk
By helping to remove toxins and radicals from the body, these injections act to lighten your skin, reduce dark spots, and provide a brighter, more even complexion
De Almeida et al
While every patients journey is unique, these results signal a promising advancement in the treatment options for people with obesity
Some of these drugs can be used to enhance training and become part of something bigger, but the concern is that people believe they are doing something beneficial for their wellbeing when that may not necessarily be the case
